Abstract
The progression of Alzheimer's disease (AD) correlates with changes in the level of cholinesterase activity, i.e., butyrylcholinesterase (BuChE) increases while acetylcholinesterase (AChE) decreases. The consequence is a decrease in the level of acetylcholine and loss of cognitive function. In addition, both enzymes are associated with neurotoxic β‐amyloid (Aβ) plaques. As such, butyrylcholinestersase inhibitors are a potential therapeutic to relieve the symptoms of AD. The BuChE specific irreversible inhibitor di‐n‐butyl 2‐chlorophenyl phosphate (DBPP) was tested for its effect on the formation of β‐amyloid and the amyloid precursor protein (APP) by ELISA and Western Blot analysis, respectively. Results of the ELISA assay showed an increase in Aβ‐40 and 42 concentration in neuroblastoma cells treated with 10‐5 M DBPP. In contrast lower. concentrations of 10‐6 M and 10‐8 M DBPP induced a lower concentration of Aβ‐40 and 42 when compared to the control.. Western Blot analysis of the cell lysate supernatant showed a decrease APP formation with 10‐5 DBPP. but little or no difference at the lower concentrations of inhibitor. Supported in part by CSUPERB and the CSULB Mini Grant Program.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
